Patent 11560437 was granted and assigned to Biomunex Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.
The invention relates to multispecific antibody constructs comprising Fab fragments having a particular set of mutations at the interface of the CH1 and CL domains, the mutations preventing heavy chain/light chain mispairing.